A significant UK study involving over 165,000 dementia patients has found that the antipsychotic drug risperidone is associated with a higher risk of stroke across all patient groups. This challenges previous assumptions that certain individuals might be safer candidates for the medication, suggesting there is no clearly “safe” group for its use.
Key Takeaways
- Risperidone, commonly prescribed for agitation in dementia patients, is linked to an increased stroke risk even in those without prior heart disease or stroke history.
- The study found no specific patient group to be entirely safe from this elevated risk.
- Current NHS guidelines recommend limiting risperidone to six weeks, but many patients use it longer, with inconsistent monitoring.
- There are no licensed alternative drugs in the UK for severe agitation in dementia patients, making careful risk-benefit discussions crucial.
Risperidone’s Role in Dementia Care
Risperidone is a potent antipsychotic frequently prescribed to individuals with dementia who experience severe agitation or aggressive behavior. It is often used in care homes when non-drug approaches fail to manage these distressing symptoms. Approximately half of all people living with dementia exhibit agitation, which can cause significant distress for both patients and their caregivers.
Stroke Risk Found Across All Patient Groups
One of the most striking findings of the study, published in the British Journal of Psychiatry, is that the increased stroke risk associated with risperidone appears consistent across different types of dementia patients. Dr. Byron Creese of Brunel University of London stated,
“We knew Risperidone causes stroke, but we didn’t know whether some groups of people might be more at risk than others.”
The research aimed to identify characteristics that might make certain patients more vulnerable, but the findings indicate a broader risk.
Findings on Stroke Risk
The research team analyzed anonymized NHS health records from 2004 to 2023. They compared dementia patients prescribed risperidone with similar patients who were not taking the drug.
- Patients with a history of stroke: The annual stroke rate per 1,000 person-years was 22.2% for those taking risperidone, compared to 17.7% for those not using the drug.
- Patients with no prior stroke: The stroke rate was 2.9% for risperidone users versus 2.2% for non-users.
- Short-term use: The study also found that stroke risk was higher among patients using the medication for shorter periods, such as 12 weeks.
Implications for Clinical Practice
These findings highlight the difficult decisions faced by clinicians and families, who must balance the drug’s ability to calm severe agitation against the potential for serious side effects like stroke. While NHS guidance suggests limiting risperidone treatment to six weeks for severe symptoms, many patients continue the medication for longer periods, and monitoring practices can vary. Dr. Creese emphasized the need for updated guidance that is more person-centered and based on specific patient characteristics, stressing that
“Every decision should be based on what is right for each person, through honest conversations between doctors, patients, and families.”
Sources
- Dementia drug raises stroke risk — even in ‘low-risk’ patients, UK study shows, Brunel University of London.